The global trend in cannabis legalization and acceptance of the plant as medicine took another leap forward recently. New Zealand’s largest medical cannabis firm and the leading British expert in medical cannabis recently joined forces to host a ‘Masterclass in Medical Cannabis’ series to educate local doctors and healthcare professionals about the benefits of incorporating the plant into their prescription.
Professor Mike Barnes, a highly experienced consultant neurologist and the Director of Education for the Academy of Medical Cannabis based in London, and Helius Therapeutics hosted three ‘Masterclass in Medical Cannabis’ events in Auckland, Wellington and Christchurch, the first RNZCGP-endorsed professional training of its kind.
Paul Manning, CEO of Helius believes it is “absolutely critical that New Zealand’s doctors have access to professional training in advance of locally-produced medicinal cannabis products becoming widely available from next year.”
“As the country’s largest medical cannabis firm, I feel it’s incumbent on Helius to invest in educational opportunities for healthcare professionals, in what is a rapidly emerging field of clinical practice,” said Manning.
We sat down with Prof. Barnes and Paul Manning to discuss the importance of education, the global trend of cannabis legalization and their mutual concern of the specialist sign-off requirement that’s recommended in the discussion document on New Zealand’s Medicinal Cannabis Scheme.
Professor Mike Barnes
Cannabis Aficionado: Why do you think doctors are so hesitant to prescribe medical cannabis?
Professor Mike Barnes: There are several reasons: lack of knowledge and lack of guidance, also medical cannabis products being unapproved medicines, which means the doctor had to take additional responsibility — so they can be scared of prescribing!
Education is key to informed decision making. In an ideal world, what educational resources would you like medical professionals to have access to?
As many different formats as possible. On-line training, one-day masterclasses like we ran in New Zealand, and written material.
What do you think the most compassionate legal cannabis model looks like?
Wide access to all that may benefit without restriction on conditions that can be treated. Leave it up to the doctor to decide whether its right for that patient (like any other medicine). Allow all doctors (specialists and GPs) to prescribe any GMP standard product.
What parallels do you believe New Zealand has with the U.K. with regards to thoughts around cannabis legalization?
Very similar — general doctor reluctance to be involved — although I felt much more interest than we have in the U.K. That’s for medical cannabis of course. General legalization for recreational use is at about 50:50 split in the U.K. now — similar again to New Zealand.
Have you seen N.Z.’s proposed medical cannabis scheme? If yes, what are your thoughts?
Yes, and it’s generally excellent. The main issue is the proposed prescribing restriction that requires specialist sign off, which is unnecessary. I believe that GPs would make very good prescribers as medical cannabis is mainly a symptom treater and GPs treat the sort of symptoms that cannabis helps all the time, such as chronic pain, anxiety, sleep problems, etc.
What three things do you wish all doctors knew about medical cannabis?
That it is very safe. It is generally different from unregulated cannabis and there is good evidence for several indications.
Any advice for New Zealand moving forward with legalization?
Make medical cannabis products available through GPs without the need for a specialist recommendation. Help all doctors to learn by organizing a range of educational opportunities. And don’t rely on the traditional medical bodies to provide guidance, as they are usually far too conservative – the wrong generation!
Paul Manning, CEO, Helius Therapeutics
Cannabis Aficionado: Why does Helius believe that educating doctors is so important?
Paul Manning: Thousands of suffering New Zealanders will be relying on their GPs for professional advice about medicinal cannabis for a range of therapeutic possibilities, and if appropriate, to access to products on prescription. We strongly believe every Kiwi has a natural right to a pain-free existence.
However, access will not improve unless doctors are well-informed about medical cannabis and how to prescribe the products. Let’s not repeat the mistakes of Australia and the U.K., where doctors were simply unprepared for the changes, causing widespread frustration among patients.
This initiative marked New Zealand’s first RNZCGP-endorsed professional training in medicinal cannabis for doctors on a national scale. It’s a major milestone for our burgeoning medicinal cannabis industry, as well as the healthcare sector.
How did Prof. Barnes become involved?
Mike became widely known after the U.K. Government commissioned him in 2016 to assess evidence for the medical use of cannabis. I had read this report, Cannabis: The Evidence for Medical Use. It helped to change the direction of legislation in the U.K. and acted as a catalyst to the eventual rescheduling of medicinal cannabis in November 2018. He is also the author of more than a dozen books and 200 published papers, several of which have been referenced by our team.
Mike also famously consulted to Alfie Dingley’s case in England, a six-year-old boy who suffers from a rare form epilepsy that was causing up to 150 seizures a month. His seizures have been since dramatically reduced after being given cannabis products. Mike is the Director of Education at The Academy of Medical Cannabis, so I reached out to him about this opportunity.
Did he enjoy himself?
Absolutely. We had an ambitious schedule, to deliver three full-day masterclasses in three cities, so we were flat out, but it was a lot of fun too! I think Mike really liked New Zealand and I know he was very encouraged by the positive response from healthcare professionals down here.
What has the feedback been from attendees?
We had 330 healthcare professionals attend the three masterclasses. The feedback has been fantastic. The majority of attendees were general practitioners. It was a big commitment to join the class for a whole day, and I think this demonstrates just how open-minded many doctors are to medical cannabis.
What is the biggest reason you believe cannabis should be legalized for medical purposes?
Cannabis is an extraordinary, natural treatment for many chronic conditions. These products present alternative to many harsh drugs, such opioids, and can improve the lives of millions of people across the world.
What is one thing you wish people knew about the therapeutic benefits of medical cannabis?
You don’t need to get high to get healthy. Even products that contain THC need not necessarily come with a euphoric effect.
How can the public educate themselves on medical cannabis?
There are some wonderful resources available online, such as Project CBD. There’s a fantastic book by the National Academies of Sciences, Engineering, and Medicine with the snappy title The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. We’re also working on a unified repository of the world’s published cannabis research, which will be launched in 2020.
Any plans for more events like this again?
You bet. The Masterclasses in Medical Cannabis were just the start. We’ll be rolling out a program of professional and public education initiatives over the next 24 months. Helius has also just signed a quarter-million dollar commitment with BiotechNZ to stage a major education event in New Zealand early next year.
The Highly Anticipated Collab Between Bllrdr x G Pen Has Dropped
G Pen has partnered with Bllrdr to introduce a new collaboration, an exclusive co-branded global line of G Pen advanced technology vaporizers, starting with the Bllrdr x G Pen Dash.
This collab integrates new cannabis products from Bllrdr with G Pen’s proprietary innovative technologies and hardware, to make for even more brand diversity of the popular G Pen vaporizers.
Helping to both elevate and advance the cannabis experience, the two companies have a shared history of innovation, something that is set to continue with each brand to bring sought-after collaborations to the market.
Bllrdr is a Toronto-based cannabis brand founded by Noah “40” Shebib, a Grammy award-winning producer, and Jef Tek, a legendary cultivator. The brand is known for its extensive market-leading cannabis genetics and small-batch production, developing rare and special cut strains.
After being diagnosed with multiple sclerosis, Shebib discovered the benefits of using the Afghani Bullrider cultivar. Tek’s late wife, medical marijuana activist Michelle Rainey, who suffered from Crohn’s disease and cancer, also found the strain offered relief from her symptoms.
G Pen, known for championing and celebrating the connection between consumption and art, is thrilled to partner with Bllrdr, Canada’s best new lifestyle cannabis brand, supporting its people and their mission.
“I’ve known Noah since the early stages of G Pen,” says G Pen CEO and founder Chris Folkerts, “and this partnership brings it full circle.”
“It’s an honor to be a part of the launch of the most highly-anticipated and unique genetics in the Ontario market.”
Now, the two brands plan to bring sought-after collaborations to the market increasing the brand diversity of the popular G Pen vaporizers by integrating new cannabis products from Bllrdr with G Pen’s proprietary innovative technologies and hardware.
This first release from the G Pen x Bllrdr Collection is well-timed, with the launch of Bllrdr’s highly anticipated Afghani Bullrider strain — considered as one of the rarest genetics on the market — now officially available on the Ontario Cannabis Store. And just like Afghani Bullrider, the Bllrdr x G Pen Dash delivers satisfying and flavorful results.
The Bllrdr x G Pen Dash is now available in select Ontario retailers and on bllrdrco.co.
5 Tips for Owning and Operating Successful Cannabis Dispensaries
The cannabis retail landscape has changed. Once regarded as somewhat of a novelty, legalization has allowed cannabis dispensaries to evolve into modern and innovative retail storefronts more akin to an Apple Store than the dark, secretive spaces they used to be. Some, like Shiny Bud, are proving to be leaders in the space, setting an exemplary standard of a contemporary cannabis retail experience.
Shiny Bud is one of Canada’s most successful dispensary chains. They pride themselves on offering customers a premium experience from the moment they enter, from a contemporary and inviting store design to highly trained staff, and of course, premium products.
Co-founder Alex Ledesma joined the cannabis industry when the Canadian government passed the Cannabis Act in 2018. She comes from a forward-thinking family of entrepreneurs, so the move to cannabis was an obvious next step.
“I saw an opportunity to be part of something big in Canada’s history, so we started following the industry, and applied for an application,” said Ledesma.
Shiny Bud opened its first dispensary in Toronto on February 14. Fast forward only a few months, and the company has opened the doors to its fifth location in a small town called Orleans, just outside of Ottawa.
“We have a pretty aggressive rollout,” said Ledesma. “Coming from a quick-service industry, we’re quite comfortable with builds and finding locations. We took our expertise from that and put it into cannabis. And it’s all completely within the family.”
Shiny Bud was awarded 75 dispensary licenses by the Canadian government. The company’s expansion plans include two more Ontario store openings this year, bringing the total number of store openings to seven. And they have no plans to slow down.
“We should be hitting 30 stores by the end of 2021. And we’re planning on maxing out to 75 stores allocated. When we stop to think about it, it can take our breath away.”
The constant march forward of legalization has created an ever-growing interest in dispensary ownership. Below, Ledesma offers up five pieces of advice for those looking to enter the cannabis game.
1. Have a Well-Trained Team That’s Focused on Customer Experience
As the industry is still so young, formal education in cannabis is still relatively scarce amongst prospective employees. For Shiny Bud, this presents an opportunity to reinforce one of their most important business objectives: provide cannabis education and training for their budtenders to pass on to their customers.
“Education is everything because the industry’s so new,” Ledesma said. “We truly believe that we’re an industry where we need to listen to our guests. This is one of the first things we teach our budtenders, along with providing a safe and educational experience for our customers in-store.”
For many customers, the biggest value in going to a dispensary is learning which products are best suited for a specific condition or effect, whether they’re seasoned cannabis consumers or newly curious.
“The goal for budtenders at Shiny Bud is to ensure customers are choosing the right product for them to provide a safe experience both in-store and at home,” Ledesma said.
2. Create a Guest Centric Environment
This goes without saying, but customer service is critical to the success of any retail operation. Ledesma attributes Shiny Bud’s success to the brand’s core vision of providing a “fast and friendly cannabis retail destination.”
“We strive to offer our customers a unique and memorable experience — this has stayed with us since day one,” Ledesma said. “When you walk into any of our Shiny Bud cannabis dispensaries, they’re bright, they’re big, and there’s a lot of education. The budtenders are dressed uniformly, and there’s personality — it’s not what people expect.”
Watching the change in customer demographic has been encouraging to Ledesma, who notes the increase in the 60+ demographic looking to add cannabis to their health and wellness, whether it be recreational, or to aid with a specific ailment.
“As a disclaimer, we always have to tell them that we’re not doctors and we can’t give them medical advice, so to start low and go slow,” Ledesma said. “It’s nice to see people like my mom, my dad, and grandparents come through the door, because you also know you’re helping break down the stigma.”
3. Stock the Best Inventory
With so many quality products now available, choosing which ones to bring to Shiny Bud is quite a lengthy process.
“We carry out a lot of research in terms of what’s new or trending, and what our customers are looking for in each location,” Ledesma said. “I wish I knew consumers’ buying preferences before our initial order was placed. We ended up buying too much!”
“We also use recommendations from our team members, our budtenders, and our customers. A lot of times we bring in representatives of the licensed producers to educate our budtenders about the products we’re selling.”
The three most popular purchases across three Shiny Bud locations are dried flower, vapes, and pre-rolls. “Our most frequently asked question is, ‘what is your highest THC or CBD?’” Ledesma said.
4. Have a Great Location
The age-old proverb of “location, location, location” rings true in the cannabis industry, too. Finding the right real estate is arguably the most important part of retail success. Plus, because of the industry’s prohibition history and the nature of the products being sold, it’s important to find understanding landlords.
“Initially, landlords have said to us, ‘absolutely not, we will not entertain the idea of having a cannabis retailer here,’ so I invite them to take a look at one of our dispensaries so they can see the vision of what and who we are as a company and as an industry.”
5. Ensure Your Cannabis Dispensaries Connect with the Community
Dispensaries are already major focal points in their communities. For Ledesma, giving back and helping break down old stigmas related to cannabis is a top priority.
Shiny Bud is in the process of launching a collaboration with Tsaichedelic to create a line of tie-dyed tees and other merchandise. The proceeds will go towards supporting Cannabis Amnesty projects, like providing legal counsel to get those with criminal records over minor cannabis charges expunged.
“Being a woman and a person of color in the cannabis space, I really believe in the fact that it needs to be the same playing fields for everybody,” Ledesma said. “Teaming up with Cannabis Amnesty just felt right.”
With the regulated cannabis market still so new, it’s important that business owners are able to adapt to changes and weather the ever-changing landscape of cannabis and the regulations.
“It’s ever-changing, so we’re constantly learning and growing from it,” Ledesma said. “Regulations are always changing, so being fluid helps a lot.”
Look for Shiny Bud cannabis dispensaries in Canada and keep an eye out for their expansion into America in 2021.
Gwyneth Paltrow and a Slew of Celebs Invest in ‘Social Tonic’ Brand, Cann
Gwyneth Paltrow is one of several high-profile celebrities investing in cannabis-infused beverage company, Cann.
Rebel Wilson, Ruby Rose, Darren Criss, Tove Lo, Casey Neistat, former NBA star Baron Davis and Bre-Z have also invested in the company.
The actress and Goop CEO and founder calls cannabis a “hero ingredient of the future” for wellness and says she was drawn to Cann’s drinks, which are infused with small doses of THC and CBD, as an appealing alternative to alcohol.
“There’s a whole sober-curious movement that’s going on and the cannabis-curious movement that’s going on, this is kind of at the intersection of those things in a way,” said Paltrow.
Cann is not the health and wellness moguls’ first cannabis investment. Paltrow admitted that while she’s not a big cannabis user personally, she acknowledges its “amazing medicinal qualities.”
“There’s no reason why alcohol should be so much easier to purchase than Cann, and I’m confident the founders will lead the charge in finding ways to integrate it into the same purchasing channels and drinking environments,” she said via a news release.
Cann founder Luke Anderson called the comments made by Gwyneth Paltrow “a sign that Cann (and microdose beverages more broadly) are a viable answer to that very common consumer pain point.”
He added that when people think of Paltrow, “they don’t think of ‘weed’ – they think of cutting-edge solutions for today’s health and wellness needs.”
Cann has positioned itself as a “healthy” and hangover-free alternative to alcohol. Most of Cann’s “social tonics” contain roughly 30 calories and are “microdosed” with 2 milligrams of THC and 4 milligrams of CBD. A recently introduced Pineapple Jalapeño flavor contains 50 calories and 5 milligrams of THC.
Earlier this year, Cann secured $5 million in funding as part of the company’s 2020 production and distribution expansion plans for 2020.
According to TechCrunch, the beverage startup has sold 150,000 cans, which retail for $4 each, since last May. Cann products are available at just 60 dispensaries in California, and online via the Eaze cannabis marketplace, making the $600,000 in revenue the company generated in less than a year even more impressive.